EOS imaging COMMUNICATES ITS ANNUAL REPORT 2017
Review of significant events of 2017 and first quarter of 2018
Discussion of financing outlook

Paris, April 30, 2018 – EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the publication of its Registration Document for the financial year closed on December 31, 2017. It has been filed with the Autorité des Marchés Financiers (AMF) under number D.18-0439 dated April 27, 2018. This document is available in French on the Company’s website (www.eos-imaging.com) under the heading "Investors", where an English version will also be posted shortly. It is also available on the AMF website (www.amf-france.org).

Significant events

The Annual report presents the progress and difficulties encountered by the Group during 2017, which saw the continued adoption of EOS by new reference institutions contribute to strengthening the strategic positioning of the Group at the global level. The Group has also continued to enrich its product offerings with services and tools dedicated to the planning of orthopedic surgical procedures.

In July 2017, to support growth in North America, EOS imaging recruited as its North America President Mike Lobinsky, who strengthened sales teams, both in number and experience in the field of sales of innovative medical equipment.

In October 2017, EOS imaging appointed Eric Maulavé, previously VP Global Sales, as Chief Operating Officer, and Didier Saint-Félix as Vice President, Transformation.

In 2017, sales of EOS imaging in Europe, Middle East and Africa increased by 45% to € 16.6 million. They represent 45% of the Group’s sales, compared to 37% in 2016.

After the reorganization and strengthening deployed in the second half of the year, the North American zone resumed growth of 40% in the last quarter of 2017, in line with the growth observed in 2016. For the whole of 2017, the turnover in the zone amounted to € 14.6 million and represented 39% of consolidated sales, compared to 50% in 2016.

In Asia Pacific, sales amounted to € 5.9 million, up 83%, mainly due to strong growth in China and Australia.

Overall, in fiscal 2017, the Group recorded 21% growth in sales, at € 37.1 million, representing a compound annual growth rate (CAGR) of 32% over the 2012-2017 period.

Financial Outlook

As of December 31, 2017, the Group's cash and cash equivalents amounted to € 6.9 million.

In order to support the growth of its business in 2018, EOS Imaging has restructured its debt with IPF:

- The amortization of the first three tranches was suspended from December 2017 until June 2019, with amortization carried forward to June 2022;
- A new tranche of 4.9 million euros was subscribed in January 2018, with partial repayment between
PRESS RELEASE

December 2021 and December 2022 and 60% in fines, without additional issue of BSA, the other conditions
being comparable to those of the previous tranche.

In the coming months, on the basis of its budget forecasts and subject to approval by the relevant
corporate bodies of the Company, EOS imaging will restructure its financing to meet its cash requirements.
As specified in Chapter 10.7 of the Registration Document and under the conditions described in the
Statutory Auditors’ Report, the Company has several options to finance its growth, which will be analyzed
by the Board of Directors.

For the record, EOS imaging posted a 34% increase in sales in the first quarter of 2018, driven notably by
sales in the North American market, which grew to a historic level of 54% over the period.

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to
osteoarticular pathologies and orthopaedics combining equipment and services and targeting a $2B per
year market opportunity. EOS imaging is currently present in 31 countries, including the United States
under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250
installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M
in 2017, e.g. a +32% CAGR over 2012-2017.
For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA - PME 150 index, composed of 150
French companies listed on the Euronext market in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI

Contacts:

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com

Press Relations (US)
Joanna Zimmerman
The Ruth Group
Ph: 646-536-7006
jzimmerman@theruthgroup.com

Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com